Managing cytokine release syndrome in relapsed/refractory multiple myeloma: experience with teclistamab in the MajesTEC-1 study

被引：0

作者：

Catamero, Donna ^{[1
]}

Benito, Patricia Blazquez ^{[2
]}

Shenoy, Samantha ^{[3
]}

Chastain, Katherine ^{[4
]}

Kruyswijk, Sandy ^{[5
]}

机构：

[1] Mt Sinai Hlth Syst, New York, NY USA

[2] Univ Hosp Salamanca, Salamanca, Spain

[3] Univ Calif San Francisco, San Francisco, CA USA

[4] Janssen Res & Dev, Raritan, NJ USA

[5] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

NSP-05

引用

页码：S315 / S316

页数：2

共 50 条

[41] Teclistamab for Relapsed/Refractory Multiple Myeloma: Real-World Experience in an Early Access Program
Uttervall, Katarina
Nahi, Hareth
Kashif, Muhammad
Lemonakis, Konstantinos
Rosengren, Sara
Brolin, Janaki
Lund, Johan
Hansson, Markus
BLOOD, 2022, 140 : 12605 - 12606
[42] Safety and Efficacy of Teclistamab in Patients with Relapsed/ Refractory Multiple Myeloma: A Real-World Experience
Dima, Danai
Davis, James A.
Ahmed, Nausheen
Jia, Xuefei
Sannareddy, Aishwarya
Shaikh, Hira
Shune, Leyla
Kaur, Gurbakhash
Khouri, Jack
Afrough, Aimaz
Strouse, Christopher
Lochner, Jonathan
Mahmoudjafari, Zahra
Raza, Shahzad
Valent, Jason
Anderson Jr, Larry D.
Anwer, Faiz
Abdallah, Al-Ola
Hashmi, Hamza
TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (03): : 308.e1 - 308.e13
[43] Long-Term Follow-Up From the MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
van de Donk, Niels W. C. J.
Moreau, Philippe
Garfall, Alfred L.
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay K.
Martin, Thomas G.
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar
Popat, Rakesh
Besemer, Britta
Martinez Lopez, Joaquin
Krishnan, Amrita
Delforge, Michel
Trancucci, Danielle
Verona, Raluca I.
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S25 - S26
[44] Teclistamab in combination with daratumumab and lenalidomide in multiple myeloma (MajesTEC-2 study)
Searle, Emma
Quach, Hang
Wong, Sandy
Costa, Luciano
Hulin, Cyrille
Janowski, Wojciech
Berdeja, Jesus
Anguille, Sebastien
Matous, Jeffrey
Touzeau, Cyrille
Michallet, Anne-Sophie
Husnik, Marla
Vishwamitra, Deeksha
Niu, Zhuolu
Larsen, Julie
Chen, Lingling
Goldberg, Jenna
Popat, Rakesh
Spencer, Andrew
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 74 - 74
[45] Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
Razzo, Beatrice
Grajales-Cruz, Ariel
Atrash, Shebli
Ferreri, Christopher
Goyal, Anmol
Pasvolsky, Oren
Banerjee, Rahul
Julian, Kelley
Forsberg, Peter
Herr, Megan
Lin, Yi
Susanibar-Adaniya, Sandra
Khouri, Jack
Vazquez-Martinez, Mariola
Lee, Hans
Portuguese, Andrew
Sborov, Douglas W.
Dima, Danai
Davis, James
Kaur, Gurbakhash
Shune, Leyla
Hansen, Doris
Sidana, Surbhi
Garfall, Alfred
Richard, Shambavi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S82 - S83
[46] Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
van de Donk, Niels
Moreau, Philippe
Garfall, Alfred
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay
Martin, Thomas
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar
Popat, Rakesh
Besemer, Britta
Martinez Lopez, Joaquin
Krishnan, Amrita
Delforge, Michel
Trancucci, Danielle
Verona, Raluca
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S477 - S478
[47] Preliminary recommendations for prevention and management of infections, hypogammaglobulinemia, and neutropenia during treatment with teclistamab based on experience from the MajesTEC-1 study
van de Donk, Niels
Nooka, Ajay
Rodriguez, Cesar
Mateos, Maria-Victoria
Chastain, Katherine
Banerjee, Arnob
Kobos, Rachel
Qi, Keqin
Verona, Raluca
Doyle, Margaret
Martin, Thomas
Manier, Salomon
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S32 - S32
[48] Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
van de Donk, Niels W. C. J.
Moreau, Philippe
Garfall, Alfred L.
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay K.
Martin, Thomas G.
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar J.
Popat, Rakesh
Besemer, Britta
Martinez-Lopez, Joaquin
Krishnan, Amrita Y.
Delforge, Michel
Trancucci, Danielle
Verona, Raluca
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[49] MajesTEC-9: A randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Touzeau, Cyrille
Hungria, Vania T. M.
Bhutani, Divaya
Landgren, Ola
Vieyra, Diego
Guo, Yue
Verona, Raluca
Miao, Xin
Qi, Mia
Watkins, Latisha
Shah, Priya
Chastain, Katherine
Qi, Ming
Quach, Hang
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[50] Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study
Manier, Salomon
Nooka, Ajay
Rodriguez, Cesar
Mateos, Maria-Victoria
Chastain, Katherine
Banerjee, Arnob
Kobos, Rachel
Qi, Keqin
Verona, Raluca
Doyle, Margaret
Martin, Thomas
van de Donk, Niels
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S480 - S481

← 1 2 3 4 5 →